Understanding how different SF3B1 mutations affect myelodysplastic syndromes
Biologic and Therapeutic Consequences of Distinct Hotspot SF3B1 Mutations in MDS
This study is looking at how certain changes in the SF3B1 gene affect people with myelodysplastic syndromes (MDS) to better understand why some patients have different symptoms and responses to treatment, with the hope of finding more effective therapies for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10877728 on NIH RePORTER |
What this research studies
This research investigates the role of specific mutations in the SF3B1 gene, which are commonly found in patients with myelodysplastic syndromes (MDS). By analyzing how these mutations impact RNA splicing and contribute to the symptoms of MDS, the study aims to uncover the underlying mechanisms that lead to variations in disease severity and treatment responses. The approach includes examining clinical data and biological samples from patients to identify patterns associated with different SF3B1 mutations. This knowledge could pave the way for more targeted and effective therapies for MDS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with myelodysplastic syndromes who have specific SF3B1 mutations.
Not a fit: Patients without SF3B1 mutations or those with other types of blood disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies tailored to the specific mutations present in MDS patients.
How similar studies have performed: Previous research has shown that understanding genetic mutations can lead to significant advancements in treatment approaches for blood disorders, indicating a promising avenue for this study.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Dalton, William Brian — Johns Hopkins University
- Study coordinator: Dalton, William Brian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.